• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Reply to Decroo : High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.回复德克鲁：复发性利福平敏感结核病的大剂量一线治疗方案
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1579-1580. doi: 10.1164/rccm.202002-0359LE.
2
High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.复发性利福平敏感结核病的大剂量一线治疗方案
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1578-1579. doi: 10.1164/rccm.202001-0201LE.
3
Pyrazinamide resistance in rifampicin discordant tuberculosis.利福平耐药结核病中的吡嗪酰胺耐药性。
PLoS One. 2022 Sep 21;17(9):e0274688. doi: 10.1371/journal.pone.0274688. eCollection 2022.
4
Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.不同抗结核药物治疗方案治疗耐多药结核病的比较：一项个体患者数据荟萃分析。
Lancet Respir Med. 2018 Apr;6(4):265-275. doi: 10.1016/S2213-2600(18)30078-X.
5
Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.耐多药结核病项目中高剂量利福平、异烟肼和吡嗪酰胺治疗的中敏剂量依赖性折点。
Clin Infect Dis. 2018 Nov 13;67(11):1743-1749. doi: 10.1093/cid/ciy346.
6
Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.采用异烟肼、利福平、乙胺丁醇和吡嗪酰胺治疗耐异烟肼结核病6个月。
Int J Tuberc Lung Dis. 2002 Nov;6(11):952-8.
7
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.贝达喹啉、莫西沙星、普托马尼和吡嗪酰胺治疗药物敏感或耐药性肺结核患者的前 8 周：一项多中心、开放标签、部分随机、2b 期临床试验。
Lancet Respir Med. 2019 Dec;7(12):1048-1058. doi: 10.1016/S2213-2600(19)30366-2. Epub 2019 Nov 12.
8
Tuberculosis in neonates and infants: epidemiology, pathogenesis, clinical manifestations, diagnosis, and management issues.新生儿和婴儿结核病：流行病学、发病机制、临床表现、诊断及管理问题
Paediatr Drugs. 2005;7(4):219-34. doi: 10.2165/00148581-200507040-00002.
9
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.在抗结核治疗的前 8 周，莫西沙星、贝达喹啉（PA-824）和吡嗪酰胺联合使用的疗效和安全性：一项在药物敏感性或耐药性肺结核患者中进行的 2b 期、开放标签、部分随机试验。
Lancet. 2015 May 2;385(9979):1738-1747. doi: 10.1016/S0140-6736(14)62002-X. Epub 2015 Mar 18.
10
Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.在一个耐药结核病发病率较低的国家，表型上对利福平敏感的结核分枝杆菌分离株中出现有争议的 rpoB 突变。
BMC Infect Dis. 2019 Jan 3;19(1):3. doi: 10.1186/s12879-018-3638-z.

本文引用的文献

1
Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial.不同异烟肼剂量对耐多药结核病的早期杀菌活性（事后回顾）：一项随机、开放标签的临床试验
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1416-1424. doi: 10.1164/rccm.201910-1960OC.
2
Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis.利福平在人类结核病中的临床药代动力学和药效学。
Clin Pharmacokinet. 2019 Sep;58(9):1103-1129. doi: 10.1007/s40262-019-00764-2.
3
Improved Outcomes With High-dose Isoniazid in Multidrug-resistant Tuberculosis Treatment in Haiti.高剂量异烟肼在海地耐多药结核病治疗中的改善结局。
Clin Infect Dis. 2019 Aug 1;69(4):717-719. doi: 10.1093/cid/ciz039.
4
Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.儿童耐多药结核病的治疗和结局：系统评价和个体患者数据荟萃分析。
PLoS Med. 2018 Jul 11;15(7):e1002591. doi: 10.1371/journal.pmed.1002591. eCollection 2018 Jul.
5
Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis.短程、高效、廉价的耐多药结核病标准化治疗方案。
Am J Respir Crit Care Med. 2010 Sep 1;182(5):684-92. doi: 10.1164/rccm.201001-0077OC. Epub 2010 May 4.

Reply to Decroo : High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.

作者信息

Dooley Kelly E, Miyahara Sachiko, von Groote-Bidlingmaier Florian, Sun Xin, Hafner Richard, Rosenkranz Susan L, Ignatius Elisa H, Nuermberger Eric L, Moran Laura, Donahue Kathleen, Swindells Susan, Vanker Naadira, Diacon Andreas H

机构信息

Johns Hopkins University School of MedicineBaltimore, Maryland.

Harvard T. H. Chan School of Public HealthBoston, Massachusetts.

出版信息

Am J Respir Crit Care Med. 2020 Jun 15;201(12):1579-1580. doi: 10.1164/rccm.202002-0359LE.

DOI:10.1164/rccm.202002-0359LE
PMID:32130866
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7301745/
Abstract
摘要